Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823491) titled 'Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ohio State University Comprehensive Cancer Center
Condition:
Resectable Liposarcoma
Resectable Soft Tissue Sarcoma
Resectable Undifferentiated Pleomorphic Sarcoma
Intervention:
Procedure: Biospecimen Collecti...